This is mainly due to age-related metabolic resistance (such as decreased IGF-1 levels) (Ahmad et al., 2020), mitochondrial dysfunction (Dulac et al., 2021), chronic low-grade inflammation (Coperchini et al., 2025), and degeneration of the neuromuscular junction (Motanova et al., 2024).Currently, there is no effective treatment for muscular atrophy; therefore, identifying risk factors that can cause muscular atrophy at an early stage and taking effective measures are crucial in preventing the occurrence of adverse events. This evidence concerns the gene IGF1 and muscular atrophy.